Stille AB (SE:STIL)
:STIL
Want to see SE:STIL full AI Analyst Report?
STIL Stock Chart & Stats
kr186.50
-kr9.00(-3.81%)
At close: 4:00 PM EST
kr186.50
-kr9.00(-3.81%)
Day’s Range― - ―
52-Week Rangekr143.00 - kr283.00
Previous CloseN/A
Volume3.08K
Average Volume (3M)6.57K
Market Cap
kr2.35B
Enterprise Valuekr2.31B
Total Cash (Recent Filing)kr138.22M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)38.0
Beta0.13
Next Earnings
Jul 23, 2026EPS Estimate
2.6Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)6.91
Shares Outstanding8,985,447
10 Day Avg. Volume9,615
30 Day Avg. Volume6,571
Financial Highlights & Ratios
PEG Ratio-7.86
Price to Book (P/B)2.48
Price to Sales (P/S)3.10
P/FCF Ratio112.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)8.7
Revenue Forecast (FY)kr689.95M
Bulls Say, Bears Say
Bulls Say
High MarginsSustained gross (~51%) and EBIT (~15%) margins indicate durable pricing power and operational efficiency in precision surgical instruments. These margins provide a recurring profitability buffer to fund R&D, product quality, and selective reinvestment, supporting stability over months.
Conservative Balance SheetA nearly debt-free balance sheet and growing equity materially reduce financial risk and interest burden. This conservatism improves flexibility for capex, product development, or opportunistic M&A and suits long sales cycles in healthcare procurement over the medium term.
Improving Free Cash FlowMaterial FCF growth (+66% TTM) and positive free cash flow show improving ability to convert operations into spendable cash. If sustained, this strengthens funding for working capital, product investment, and shareholder actions without relying on external financing.
Bears Say
Weak Cash ConversionOperating cash flow covers only ~31% of net income and FCF is ~54% of net income, reflecting working-capital swings or timing differences. This reduces the reliability of reported earnings as a source of spendable cash and can constrain investment or distributions over months.
Uneven Revenue TrendRevenue has shown step changes and recent near-flat annual results, increasing forecasting uncertainty. For a med-tech company reliant on hospital procurement cycles, this unevenness complicates capacity planning, margin leverage realization, and multi-quarter revenue visibility.
Modest Returns On EquityROE around the mid-single-digit to low-double-digit range (~8%) indicates only modest efficiency in converting equity into profits. Over the medium term this limits potential shareholder returns versus peers and highlights room to improve capital allocation or operational productivity.
STIL FAQ
What was Stille AB’s price range in the past 12 months?
Stille AB lowest stock price was kr143.00 and its highest was kr283.00 in the past 12 months.
What is Stille AB’s market cap?
Stille AB’s market cap is kr2.35B.
When is Stille AB’s upcoming earnings report date?
Stille AB’s upcoming earnings report date is Jul 23, 2026 which is in 38 days.
How were Stille AB’s earnings last quarter?
Stille AB released its earnings results on Apr 24, 2026. The company reported kr2.315 earnings per share for the quarter, beating the consensus estimate of kr1.958 by kr0.357.
Is Stille AB overvalued?
According to Wall Street analysts Stille AB’s price is currently Overvalued.
Does Stille AB pay dividends?
Stille AB pays a Annually dividend of kr1.8 which represents an annual dividend yield of N/A. See more information on Stille AB dividends here
What is Stille AB’s EPS estimate?
Stille AB’s EPS estimate is 2.6.
How many shares outstanding does Stille AB have?
Stille AB has 8,985,447 shares outstanding.
What happened to Stille AB’s price movement after its last earnings report?
Stille AB reported an EPS of kr2.315 in its last earnings report, beating expectations of kr1.958. Following the earnings report the stock price went up 12.391%.
Which hedge fund is a major shareholder of Stille AB?
Currently, no hedge funds are holding shares in SE:STIL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Stille AB
Stille AB is a Swedish-headquartered company, operating globally, that specializes in the design, manufacture, and sale of surgical instruments. Their extensive portfolio of medical tools encompasses a wide variety of items such as specialized forceps (including artery, ligature, wire twisting, and general types), bone-cutting instruments like cutters and rongeurs, various clamps, curettes, raspatories, elevators, needle holders, micro instruments, osteotomes, chisels, retractors, skin hooks, and scissors. Additionally, they provide C-arm tables. These products are essential for a broad range of surgical disciplines, including ERCP/abdominal fluoroscopy, neuro/spine, pain management, urology, and vascular surgeries, as well as general open surgical procedures. Beyond product provision, Stille also offers crucial post-sales support services, such as instrument repair, routine maintenance, and thorough inspections. The company leverages strategic partnerships, notably a collaboration agreement with GE Healthcare and a distribution arrangement with Synovis Micro. Its sales strategy involves direct customer engagement, distribution networks, and supply to OEM manufacturers of C-frame systems. Founded in 1841 and headquartered in Torshälla, Sweden, Stille AB operates as a subsidiary of Linc AB.